Skip to content
Insider tapeFilings through Fri, Oct 2
Watchlist
BIIB

Biogen insider trading

Health Care · Net selling
Close · Oct 5, 2026 $223.59 +45.1% over 12 months

Share price and insider trades

BIIB closeInsider buyInsider sale
100150200250NovDecJan 2026FebMarAprMayJunJulAugSepOctBought $585 on 2026-02-12 · Nicole MurphySold $119,169 on 2026-08-04 · Lloyd MinorSold $120,581 on 2026-08-03 · Lloyd MinorSold $134,116 on 2026-02-02 · Priya SinghalSold $531,548 on 2026-02-09 · Priya Singhal
Bought, 12 months$0
Sold, 12 months$905K
Insiders buying0
Insiders selling2

Valuation, profit and volume

P/E (trailing)39.7Sector median 24.5
Market value$33.04BDrug Manufacturers - General
Profit margin8.3%Revenue growth +3.4%
Volume vs. 50-day1.4×Last 5 sessions
Insiders' paper profit+$86On all tracked purchases +14.6%

Summary

Over the past 12 months, 0 Biogen insiders reported open-market purchases totaling $0, while 2 insiders reported sales totaling $905K. 4 of 4 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

Insider transactions

Open-market purchases and sales. 74 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Aug 5SEC Lloyd MinorDirector Sell Plan 593 $203.34 $121K +10.0% —
Aug 5SEC Lloyd MinorDirector Sell Plan 593 $200.96 $119K +11.3% —
Feb 17SEC Nicole MurphyHead Of Pharm Ops And Tech Buy 3 $195.03 $585 +14.6% —
Feb 10SEC Priya SinghalHead Of Development Sell Plan 2,660 $199.83 $532K +11.9% —
Feb 3SEC Priya SinghalHead Of Development Sell Plan 748 $179.30 $134K +24.7% —

Insiders at Biogen

InsiderBoughtSoldLast filingScore
Priya SinghalHead Of Development — $666K Feb 10, 2026 —
Lloyd MinorDirector — $240K Aug 5, 2026 —
Nicole MurphyHead Of Pharm Ops And Tech $585 — Feb 17, 2026 —
Maria C FreireDirector — — Jun 11, 2026 —
Menelas N PangalosDirector — — Jun 11, 2026 —
Monish D PatolawalaDirector — — Jun 11, 2026 —
Susan LangerDirector — — Jun 11, 2026 —
Jesus B MantasDirector — — Jun 11, 2026 —
Eric K RowinskyDirector — — Jun 11, 2026 —
Stephen A SherwinDirector — — Jun 11, 2026 —
William A HawkinsDirector — — Jun 11, 2026 —
Adam KeeneyHead Of Corporate Development — — May 5, 2026 —
Sean GodboutChief Accounting Officer — — Apr 3, 2026 —
Christopher ViehbacherCEO, President — — Feb 10, 2026 —
Susan H AlexanderGeneral Counsel — — Feb 10, 2026 —
Ginger GregoryEvp, Human Resources — — Feb 10, 2026 —
Robin KramerCFO — — Feb 10, 2026 —
Rachid IzzarHead Of Global Product Strat. — — Feb 10, 2026 —
Jane GroganHead Of Research — — Feb 10, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • BSXBoston Scientific$9.5M bought
  • PFEPfizer$3.0M bought
  • COOCooper Companies (The)$1.9M bought
  • ELVElevance Health$1.4M bought
  • PODDInsulet Corporation$162K bought
  • SYKStryker Corporation$27K bought

Common questions about BIIB insiders

Are Biogen insiders buying BIIB stock?

In the past 12 months, 0 insiders reported open-market purchases of BIIB worth $0. The latest was Head Of Pharm Ops And Tech Nicole Murphy bought $585 of BIIB at $195.03 — first open-market purchase in our records.

Are Biogen insiders selling BIIB stock?

2 insiders reported sales worth $905K over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.